Study of BM230 plus PD-1 drug for HER2-related advanced cancers
Part of Cancer clinical trials.
This trial tests a new two-drug combination (BM230 plus a PD-1 inhibitor) for people with advanced cancers that have certain HER2 changes. It's for those whose cancer has grown after standard treatments, and aims to see if the combination is safe and slows cancer progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer that is advanced (has spread) and has a specific HER2 change (like a gene change or high protein level).
- You are at least 18 years old, feel well enough to do daily activities, and your doctors expect you to live at least 3 more months.
- You have tried at least one standard treatment for your cancer that has stopped working or caused bad side effects.
- You haven't had a treatment that directly targets HER2 (like Herceptin) before, but you may have had other HER2 treatments.
- You are willing to provide a tumor sample (from a past surgery or a new biopsy) and have at least one cancer spot that can be seen on a scan.
- Your organs (heart, liver, kidneys, bone marrow) are working well enough based on blood tests, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BM230 for people with advanced solid tumors that have HER2 protein or gene changes. It aims to see if the drug is safe and effective for those who have run out of standard treatment options.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This trial tests a combination of two investigational drugs, MHB036C and MHB039A, in people with advanced breast cancer or other solid tumors that have spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs—peginterferon alfa-2b and an anti-PD-1 antibody—for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and whether it can shrink tumors or slow their growth.
This trial tests two new drugs, P1101 and P1801, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.